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We performed an ecological study using sentinel 
consultation data from a medical deputising service 
to assess the impact of increasing coverage with 
childhood varicella vaccine on the incidence risk of 
varicella and zoster in the population served by the 
deputising service in Victoria, Australia from 1998 to 
2012. Following a successful vaccination programme, 
the incidence of varicella in Australia was modelled 
to decrease and the incidence of zoster to increase, 
based on a theoretical decrease in boosting of zoster 
immunity following a decrease in wild varicella virus 
circulation due to vaccination. Incidence risks (con-
sultation proportions for varicella and zoster) were 
directly age-standardised to the Melbourne popula-
tion in 2000, when varicella vaccine was first availa-
ble. Age-standardised varicella incidence risk peaked 
in 2000 and halved by 2012. Age-standardised zoster 
incidence risk remained constant from 1998 to 2002, 
but had almost doubled by 2012. The increase in zos-
ter consultations largely reflected increases in people 
younger than 50 years-old. Although causality can-
not be inferred from ecological studies, it is generally 
agreed that the decrease in varicella incidence is due 
to increasing varicella vaccine coverage. The possible 
indirect effect of the vaccine on zoster incidence is less 
clear and ongoing monitoring of zoster is required. 
Introduction
In 1998 the World Health Organization recommended 
adding varicella vaccine to routine childhood vaccina-
tion schedules where it could be shown to be of rela-
tive public health and socio-economic importance, 
where it was affordable and where sustained coverage 
could be achieved [1]. The United States had imple-
mented universal childhood varicella vaccination three 
years earlier, leading to a decline in varicella incidence, 
related deaths and hospitalisations [2]. In 2004 the 
European Working Group on Varicella recommended 
routine varicella vaccination for all healthy children 
between 12 and 18 months and for all susceptible 
children before their 13th birthday, and catch-up vac-
cination in older children and adults without a reliable 
history of varicella and who were at risk of transmis-
sion and exposure [3]. The introduction of varicella 
vaccine into the childhood schedule with subsequent 
significant decrease in varicella in the community has 
been reported from Navarre in Spain [4] and Bavaria in 
Germany [5] but not all European countries have a uni-
versal varicella vaccine programme [6].
Part of the reluctance to introduce universal varicella 
vaccination in some European countries was related 
to the theoretical possibility that high coverage with 
varicella vaccine in children would lead to an increase 
in zoster. This possibility is based on the hypothesis 
that T-cell-mediated immunity to zoster is boosted by 
repeated exposure to circulating wild varicella virus 
and that this boosting will decrease following the 
decrease in circulating wild virus due to varicella vacci-
nation. This is known as the Hope-Simpson hypothesis 
[7]. Assuming this hypothesis to be true, modelling in 
England [8-10], Finland [11], the United States [12] and 
Australia [13] suggested an increase in zoster incidence 
for as many as 60 years would accompany a decrease 
in varicella incidence following widespread use of 
varicella vaccine in childhood. Australia nonetheless 
licensed varicella vaccine in 2000 and added it to the 
publicly funded national immunisation programme in 
November 2005 for all children 18 months of age, with 
a catch-up vaccine for children aged from 10 to <14 
years. From 1 July 2013 the monovalent vaccine was 
replaced with a combined measles-mumps-rubella-
varicella (MMRV) vaccine [14]. Varicella vaccine cov-
erage for children aged less than 2 years in Australia 
was estimated as 83% by March 2011 [15] but sufficient 
doses of vaccine had been distributed in the state of 
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Victoria by 2002, prior to public funding, to cover up to 
70% of children aged 12 months and a decline in vari-
cella hospitalisations had been noted from 2000 [16]. 
Zoster vaccine was not available in Australia during the 
years of the study (1998 to 2012).
Following the introduction of varicella vaccine, a variety 
of approaches have been used to monitor varicella and 
zoster incidence (reviewed in Reynolds et al. [17]). All 
reviewed studies documented a decrease in varicella 
incidence but no change, or an increased incidence, 
in zoster. More recent studies from the United States 
have shown increases in zoster incidence in age groups 
ranging from 40 to 65 years, but often these increases 
were seen before the introduction of varicella vaccine 
[18-20]. A gradual increase in zoster incidence, both 
before and after varicella vaccination, has also been 
seen in Canada [21], Australia [16] and China [22].
Using data from Victoria, Australia’s second most 
populous state (population in 2010 approximately 
5.6 million [23]), we have previously demonstrated 
the predicted decrease in the number of cases hospi-
talised for varicella and described an increase in the 
number of hospitalisations for zoster that began before 
the introduction of varicella vaccine [16]. However, a 
recent Australian study showed a slight decrease in 
age-standardised zoster hospitalisations, and noted 
that trends in non-hospitalised disease would need to 
be monitored [24]. In the current study we have used 
community-derived data from 1998 to 2012 from a dep-
utising medical service, fulfilling the role of a general 
practice sentinel surveillance scheme, to investigate 
the modelled changes in varicella and zoster incidence 
related to the introduction of a universal childhood var-
icella vaccination programme in Australia.
Methods
We used sentinel data from a Melbourne-based medi-
cal deputising service, known as the National Home 
Doctor Service [25], which provides after-hours (after 4 
p.m. on weekdays and at any time during the weekend) 
medical treatment on behalf of 650 general practices 
in Melbourne and Geelong, the two largest population 
centres in Victoria. Deputising service doctors are all 
general practitioners (GPs), working in a service that 
has been operating for more than four decades and 
which was accredited by the Royal Australian College 
of General Practitioners in 2002. Patients are typi-
cally those who would be seen with acute problems 
in general practice but are instead visited at home or 
in an aged-care facility. The ageing of the population 
and increasing demand on GPs to visit elderly patients 
in their homes or aged-care facility has meant that 
the deputising service has an increasingly elderly 
patient base. Total consultations have increased from 
approximately 73,000 in 1998 to 149,000 in 2012 (data 
extracted from the deputising service database). GPs 
enter the details of each consultation into a purpose-
designed database that includes a free-text diagnosis 
field. All entries are subject to quality assurance.
The Victorian Infectious Diseases Reference Laboratory 
has password-protected access to the clinical database 
maintained by the deputising service. Ethical approval 
for the ongoing use of deputising service data for 
Figure 1
Deputising service consultations for varicella, age standardised and by age group, Victoria, Australia, 1998–2012
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surveillance was granted by the Human Research Ethics 
Committees at the Victorian Department of Health in 
October 2002. We conducted searches for consulta-
tions with ‘chicken’/’varicella’ or ‘zoster’/’shingles’ 
recorded in the diagnosis field between 1998 and 
2012. Data were extracted by week of consultation and 
age. We grouped the data into the age groups 0–4, 
5–9, 10–19, 20–49 and ≥50 years for varicella and <50, 
50–59, 60–69, 70–79 and ≥80 years for zoster and cal-
culated the incidence risk for varicella and zoster as 
the age-specific proportion of consultations per 1,000 
patients (hereafter referred to as the incidence risk) for 
all study years.
We then directly age-standardised the deputising ser-
vice consultation proportion (incidence risk) estimates 
to the Melbourne population in 2000 [23]. We further 
analysed data according to the three periods of vaccine 
availability: (i) pre-2000, when no vaccine was avail-
able; (ii) 2000–05, when vaccine was available on the 
private market; and (iii) after 2005, when the vaccine 
was funded by the national immunisation programme. 
Proportions were compared using a two-sample test 
of proportions. Trends in the age-specific and age-
standardised proportions over the period of the study 
were analysed using a non-parametric test for trend 
developed by Cuzick as an extension of the Wilcoxon 
rank sum test (STATA version 10.0; StataCorp LP). For 
all analyses we accepted p<0.05 as the threshold for 
statistical significance.
Results
The age-standardised varicella incidence risk rose 
from 5.0 per 1,000 patients in 1998 to 5.6 per 1,000 
patients in 2000 (p=0.157), and then fell to 2.0 per 
1,000 patients in 2012 (p for trend=0.001 from 1998 
to 2012) (Figure 1). In the shorter period from 2005, 
since the introduction of varicella vaccine into the pub-
licly funded national immunisation programme, the 
age-standardised varicella incidence risk fell from 4.3 
per 1,000 patients to 2.0 per 1,000 patients in 2012 (p 
for trend=0.023). The age-standardised varicella inci-
dence risk decreased significantly over each period of 
vaccine availability. During the period of no vaccine 
(1998 to 1999) the incidence risk was 5.2 per 1,000 
patients. It subsequently decreased to 4.7 per 1,000 
patients during the period of availability on the private 
market (2000 to 2005) and fell again to 2.5 per 1,000 
patients during the period when the vaccine was pub-
licly funded (2006 to 2012) (Table).
Age-group specific varicella incidence risk decreased 
significantly for all age groups during 2000 to 2012 (p 
for trend<0.01 for all except those aged 50 years and 
older, p=0.02) (Figure 1). Varicella incidence risk cal-
culated for each period of vaccine availability showed 
Table 
Number and proportion per 1,000 consultations of varicella and zoster cases by age group and period of varicella vaccine 
availability, Victoria, Australia, 1998–2012
Cases by age group in years and age-standardised 
risk
1998–99
Pre-vaccine
n (proportion per 
1,000 consultations)a
2000–05
Private market
n (proportion per 
1,000 consultations)a
2006–12
Publicly funded
n (proportion per 1,000 
consultations)a
Varicella
0–4 160 (14.96) 369 (12.84) 415 (6.93)b,c
5–9 95 (21.29) 229 (19.21) 265 (11.27)b,c
10–19 66 (11.07) 137 (8.75) 128 (4.54)b,c
20–49 146 (3.01) 288 (3.10) 205 (1.61)b,c
≥50 13 (0.16) 45 (0.19) 60 (0.12)c
Total 480 (3.06) 1.068 (2.67)d 1.073 (1.39)b,c
Age-standardised risk of varicella consultations 5.22 4.70d 2.54b,c
Zoster
<50 40 (0.58) 140 (0.94)d 285 (1.15)b
50–59 15 (1.04) 72 (2.27)d 152 (3.33)b,c
60–69 32 (2.57) 79 (2.46) 200 (3.90)b,c
70–79 71 (3.32) 183 (3.23) 370 (3.75)
≥80 137 (4.03) 429(3.57) 1016 (3.15)b,c
Total 295 (1.87) 903 (2.26)d 2023 (2.62)b,c
Age-standardised risk of zoster consultations 1.03 1.41d 1.81b,c
a  Unless otherwise indicated.
b  p<0.05 for comparison 1998–99 and 2006–12.
c  p<0.05 for comparison 2000–05 and 2006–12.
d  p<0.05 for comparison 1998–99 and 2000–05
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small decreases for people aged under 20 years 
between 1998 to 1999 (no vaccine) and 2000 to 2005 
(privately available). However, statistically significant 
decreases were seen after the vaccine was publicly 
funded (2006 to 2012) (Table). The age distribution of 
varicella consultations remained similar over the three 
periods of different vaccine availability, with the high-
est proportion of varicella consultations among 5 to 9 
year-olds, followed by under 5 year-olds. Varicella con-
sultations remained very uncommon in patients aged 
at least 50 years (Table).
Changes in zoster incidence risk between 1998 and 
2012 were not as clear as those for varicella. Although 
there was a significant increase in the age-standard-
ised zoster incidence risk, ranging from 1.0 per 1,000 
patients in 1998 to 1.8 per 1,000 patients in 2012 (p 
for trend=0.005), the change was not uniform. The 
increase was significant in people aged younger than 
70 years (p for trend <0.01 for people aged under 60 
years and p for trend=0.02 for 60–69 year olds (Figure 
2)) but there was no increase for people aged 70 years 
and over. When the data were collapsed into the three 
periods of vaccine availability, the incidence risk for 
those aged less than 70 years increased, consistent 
with the trend data (Table 1). However, a significant 
decrease was seen in zoster incidence risk of cases 
aged 80 years and older across each period of vaccine 
availability (Table).
Discussion
In the 15 years from 1998 to 2012, the age-standard-
ised varicella incidence risk, estimated from medical 
consultations at the deputising service, halved while 
the age-standardised incidence risk of zoster almost 
doubled. Both changes were statistically significant 
when analysed according to distinct periods of vaccine 
availability. We have used consultation proportions as 
a measure of incidence risk in a specific patient group 
because we were unable to determine the popula-
tion base of the deputising service and thus were not 
able to calculate population-based incidence rates. 
However, the recent study from Bavaria, Germany, also 
used population proportions in sentinel paediatric 
practices to describe a change in the varicella infection 
pattern in the community [5]. The decrease in varicella 
incidence risk is consistent with our previous results 
based on hospital discharge data [16] and reports from 
other countries [4,5,26].
We have also previously reported an increase in zoster 
incidence in hospital data, as predicted by modelling 
[13], largely driven by an increase in those aged over 
80 years [16]. Deputising service data by age were not 
available to us at the time of our earlier report, and the 
overall number of zoster consultations (not age stand-
ardised) was observed to increase from 2001 [16]. 
Although the deputising service data reported here 
indicate variability in zoster consultations, we have 
described a clear increasing trend in presentations for 
zoster in community patients younger than 70 years, 
and found some indication of a decreased number of 
consultations for zoster in the community among those 
aged 80 years and older. A mixed picture of age-related 
changes in zoster has been reported from various data 
sources in various countries [18,19,27,28]. However, 
compared with many other countries, Australia has 
relatively high childhood varicella vaccine coverage, 
Figure 2
Deputising service consultations for zoster, age standardised and by age group, Victoria, Australia, 1998−2012
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which may impact on zoster, as well as varicella, inci-
dence. An increase in zoster incidence among younger 
patients, for any reason, may be easier to detect in 
the community, since these patients will be less likely 
to require hospitalisation for zoster and may not be 
detected in studies of inpatients. On the other hand, 
changes in zoster incidence among older patients, 
especially those older than 80 years, may be easier 
to detect in hospitalised patients [16,24], whether due 
to disease severity or changed thresholds for hospital 
admissions among the elderly.
Our study has a number of limitations. The feasibil-
ity of using general practice sentinel surveillance to 
monitor varicella and zoster has recently been dem-
onstrated in Spain [29], but a deputising service is not 
often used for sentinel surveillance. However Victorian 
data from the National Home Doctor Service have pre-
viously demonstrated comparable evidence on influ-
enza-like illness in the community to that provided 
by other sentinel practices in Victoria [30]. We have 
recently extended this comparison to revise thresh-
olds for influenza surveillance in Victoria and have 
demonstrated that the two sentinel systems detect 
influenza community circulation within one week of 
each other [31]. The deputising service is also used to 
monitor gastroenteritis in the community in Victoria 
and has shown concordance between gastrointestinal 
illnesses seen by GPs from the deputising service and 
community-based outbreaks due to norovirus [32]. The 
concordance between sentinel deputising service and 
sentinel general practice surveillance for influenza-like 
illness and gastroenteritis demonstrates the applica-
bility of the deputising service to community-based 
surveillance of infectious diseases.
Surveillance detects only a proportion of all disease. 
Less severe cases of varicella and zoster are not likely 
to present to any medical service, including the dep-
utising service, while more severe cases will present 
to a hospital. There are also differences between the 
deputising service and clinic-based general practice. 
Whereas the five most common reasons for presenta-
tions to Australian general practices in 2009–10 were 
for prescriptions, a general check-up, having a pathol-
ogy test or reviewing results, providing an immunisa-
tion and fever [33], the five most common reasons for 
deputising service consultations were falls, respiratory 
tract infection, review (unspecified), gastroenteritis 
and urinary tract infection (data extracted from the 
deputising service database). This difference confirms 
that the deputising service is more likely to see patients 
with an acute problem. However changes in those who 
consult, in treatment-seeking behaviour or the health-
care system could have influenced the trends we have 
reported.
The deputising service covers most of the Melbourne 
and Geelong metropolitan areas, which includes a 
large and diverse population. Data on socio-economic 
status or other determinants of health are not routinely 
collected by the deputising service. While people who 
use the deputising service may not be representative 
of those who consult in general, there is no financial 
disincentive to use the deputising service, as consul-
tations are free to the patient at the time of consulta-
tion. This has not changed during the study period. The 
population base for deputising service consultations 
among those aged less than 50 years remained rela-
tively constant over the study period, making it likely 
that the increase in zoster consultations seen in this 
age group is not a result of overall changes in the pro-
portion of this age group consulting.
However, the proportion of older patients seen by 
the deputising service GPs increased substantially. 
In 2000, 25% (14,947/60,329) of patients were aged 
80 years and above, but this had increased to 39% 
(61,110/157,025) by 2012. These variations do not affect 
trends in proportions within age groups and we have 
controlled for these changes in summary data by direct 
age standardisation to the Melbourne population in 
2000. 
We did not validate the diagnosis fields used by the 
deputising service and it is possible that the search 
algorithm may generate some false positives where 
entries such as ‘query chickenpox’ would be counted 
as an episode of varicella. However, we extracted the 
same diagnosis terms for all years, assuming biases 
and anomalies that might be present would not change 
by year. Quality assurance should minimise misspell-
ing that may otherwise result in missed records using 
text-based search terms.
Although ecological studies cannot be used to infer 
causality they are nonetheless used as evidence to sup-
port the success of vaccination programmes, includ-
ing the childhood varicella programme in Victoria and 
elsewhere. Where the relationship is less direct, as 
with varicella vaccination and zoster, it is more diffi-
cult to make an inferential connection. We are not able 
to conclude that the increase in zoster incidence risk 
in community patients seen by the deputising service 
GPs is caused by high coverage with varicella vaccine, 
as has been suggested by modelling studies. Equally, 
we cannot conclude that increasing varicella vaccine 
coverage does not, or will not, play a role in transient 
increasing zoster incidence within the community. 
These community-based data add to growing evidence 
of increasing zoster – for whatever reason – and high-
light the need for multiple surveillance systems that 
track different population groups or different levels 
of illness severity for the decades over which zoster is 
modelled to change [9,12,24]. The increase in zoster 
suggests that the introduction of an adult zoster vac-
cination programme could be beneficial, depending on 
the age of vaccine administration, the effectiveness of 
the vaccine and the duration of protection [34]. 
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